Guidelines for the targeted antifungal therapy of invasive fungal infection in pediatric hematology-oncology
2015
Abstract
Invasive fungal infections (IFI) in immunocompromised children are associated with significant morbidity and mortality. Early targeted therapy is the key factor for successful outcome.
However, treatment options against IFI in children are limited. Not always it is easy to timely and to accurately confirm the diagnosis of IFI and properly identify the etiologic agent.
Use of several available potent antifungals in children is complicated by the lack of pharmacokinetic and safety data. In our report, we would like to summarize current recommendations for targeted antifungal therapy in pediatric hemato-oncology based on our experience and recommendations published during the last years.